We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Generation Bio Co (GBIO) USD0.0001

Sell:$1.11 Buy:$1.12 Change: $0.07 (6.60%)
NASDAQ:0.16%
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Sell:$1.11
Buy:$1.12
Change: $0.07 (6.60%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Sell:$1.11
Buy:$1.12
Change: $0.07 (6.60%)
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.

Contact details

Address:
301 BINNEY STREET
CAMBRIDGE
02142
United States
Telephone:
+1 (857) 5295908
Website:
https://generationbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GBIO
ISIN:
US37148K1007
Market cap:
$70.80 million
Shares in issue:
66.79 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Cameron Mcdonough
    President, Chief Executive Officer, Director
  • Matthew Norkunas
    Chief Financial Officer
  • Antoinette Paone
    Chief Operating Officer
  • Matthew Stanton
    Chief Scientific Officer
  • Phillip Samayoa
    Chief Strategy Officer
  • Yalonda Howze
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.